Annals of Oncology 15:526-536, 2004
© 2004 European Society for Medical Oncology
Original Paper |
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
Received 27 August 2003; revised 28 November 2003; accepted 19 December 2003Background:
Delayed chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect of cancer chemotherapy. We assessed, under current practice patterns, the occurrence and impact on healthcare resource utilization of CINV in patients receiving emetogenic chemotherapy. An additional aim of this study was to estimate costs imputable to CINV in the German healthcare environment.
Materials and methods:
This prospective, multi-center, cross-sectional cost-of-illness study was conducted in three hospitals and in three office-based facilities in Germany. Consecutive patients undergoing emetogenic chemotherapy (levels 4 or 5 according to Hesketh classification of emetogenicity) were enrolled. Data were obtained from preplanned chart reviews and from self-administered patient questionnaires. Analysis of direct costs was performed from the perspectives of third party payer (statutory sick fund), provider (hospital) and patients. Indirect costs were assessed on the basis of paid workdays lost.
Results:
During the 5-day observation period, 134 of 208 chemotherapy cycles observed (64.4%) were associated with at least one episode of nausea or vomiting. More patients experienced delayed than acute CINV (60.7% versus 32.8%), and more patients reported nausea than vomiting (62.5% versus 26.0%). A total of 68 patients (32.6%) utilized healthcare resources due to CINV. The most frequently used resources were rescue medications and outpatient hospital and office physician visits. Only one patient required hospitalization and only three patients lost workdays due to CINV. Average costs imputable to CINV per patient (with or without CINV) per treatment cycle incurred by third party payers and hospital providers were 
49 and 48, respectively. Patient or treatment characteristics that were associated with high costs imputable to CINV were as follows: cisplatin-containing regimen; experience of emesis; and presence of delayed CINV.
Conclusions:
A substantial proportion of patients continue to experience CINV. This entails not only clinical but also economic consequences, and highlights a continuing need for improved utilization of existing antiemetic agents and for new, more efficacious treatments. The greatest improvements in patient care and potential for cost offset may be realized by preventing delayed CINV.
1 Department of Pharmacy, Klinikum rechts der Isar, Technische Universität München; 2 MERG, Medical Economics Research Group, Munich; 3 Third Medical Department, Klinikum rechts der Isar, Technische Universität München, Germany; 4 Merck & Co., Inc., Whitehouse Station, NJ, USA; 5 Department of Clinical Pharmacology, University of Vienna Medical School, Vienna, Austria
Key words: chemotherapy-induced nausea and vomiting, cost-of-illness, healthcare utilization, health economics, healthcare provider, third party payer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]
|
|